US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Scienture Holdings, Inc.

0.4056

+0.00561.40%

Volume:60.82K

Turnover:24.50K

Market Cap:16.48M

PE:-0.24

High:0.4104

Open:0.3970

Low:0.3903

Close:0.4000

52wk High:3.61

52wk Low:0.3900

Shares:40.63M

Float Shares:33.99M

Volume Ratio:0.64

T/O Rate:0.18%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.7229

EPS(LYR):2.69

ROE:-24.07%

ROA:-10.87%

PB:0.20

PE(LYR):0.15

Loading ...

Overview Company News Filings

BUZZ-U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney

BUZZ-Scienture jumps after expanding access to hypertension drug

Scienture Holdings Reaffirms Q1 2026 Growth Outlook

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

BUZZ-Scienture Holdings jumps after U.S. FDA clears opioid overdose spray

Scienture Announces Issuance of Orange Book-Listable Patent Covering Rezenopy™, the Highest Dosage Naloxone Hcl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

THOMSON REUTERS

EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment

Benzinga_recent_news

BRIEF-Scienture Provides Update On The Commercial Launch Of Rezenopy

Scienture Holdings Launches High-Strength REZENOPY Naloxone Nasal Spray in U.S. Market

Scienture Holdings Inc - Rezenopy Expected Commercially Available Early Q2 2026

THOMSON REUTERS

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

Why Is Scienture Stock Gaining Today?

Benzinga_recent_news

BRIEF-SCIENTURE And BlinkRx Announce Strategic Collaboration To Expand Patient Access To Arbli, The First FDA-Approved Ready-To-Use Oral Suspension Of Losartan Potassium

Scienture and Blinkrx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

THOMSON REUTERS

Scienture Holdings Inc - Arbli Expected on Blinkrx Platform in Q1 2026

THOMSON REUTERS

SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025

Scienture Holdings Inc. held annual shareholder meeting

Scienture reports Q3 EPS (19c) vs. ($1.34) last year

SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SCNX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SCNX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCNX\",,,,,undefined,":{"symbol":"SCNX","market":"US","secType":"STK","nameCN":"Scienture Holdings, Inc.","latestPrice":0.4056,"timestamp":1771430629516,"preClose":0.4,"halted":0,"volume":60817,"delay":0,"changeRate":0.013999999999999985,"floatShares":33992500,"shares":40630815,"eps":-1.7229,"marketStatus":"Trading","change":0.0056,"latestTime":"02-18 11:04:02 EST","open":0.397,"high":0.4104,"low":0.3903,"amount":24502.029589420003,"amplitude":0.05025,"askPrice":0.409,"askSize":480,"bidPrice":0.4021,"bidSize":390,"shortable":3,"etf":0,"ttmEps":-1.7229,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771448400000},"marketStatusCode":2,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":0.4,"preHourTrading":{"tag":"盘前","latestPrice":0.4001,"preClose":0.4,"latestTime":"09:22 EST","volume":13496,"amount":5400.164602,"timestamp":1771424560809,"change":0.0001,"changeRate":0.00025,"amplitude":0.05},"postHourTrading":{"tag":"盘后","latestPrice":0.4168,"preClose":0.4,"latestTime":"19:38 EST","volume":9877,"amount":4034.6736,"timestamp":1771375091891,"change":0.0168,"changeRate":0.042,"amplitude":0.05775},"volumeRatio":0.642841},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCNX\",,,,,undefined,":{"symbol":"SCNX","floatShares":33992500,"roa":"-10.87%","roe":"-24.07%","lyrEps":2.685903,"volumeRatio":0.642841,"shares":40630815,"dividePrice":0,"high":0.4104,"amplitude":0.05025,"preClose":0.4,"low":0.3903,"week52Low":0.39,"pbRate":"0.20","psRate":"25.22","week52High":3.61,"institutionHeld":0,"latestPrice":0.4056,"committee":-0.103448,"eps":-1.7229,"divideRate":0,"volume":60817,"delay":0,"ttmEps":-1.7229,"open":0.397,"prevYearClose":0.51,"prevWeekClose":0.433,"prevMonthClose":0.4543,"prevQuarterClose":0.51,"fiveDayClose":0.464,"twentyDayClose":0.4962,"sixtyDayClose":0.5848},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SCNX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"SCNX","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.19},{"market":"US","date":"2025-08-12","symbol":"SCNX","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.48},{"market":"US","date":"2025-05-12","symbol":"SCNX","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"post","actualEps":-0.33},{"market":"US","date":"2025-03-26","symbol":"SCNX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1742961600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-11-06","symbol":"SCNX","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"pre","actualEps":-1.34}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SCNX\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-25","recordDate":"2024-03-18","paymentDate":"2024-03-22","value":8,"currency":"USD"},{"executeDate":"2024-07-19","recordDate":"2024-07-19","paymentDate":"2024-07-24","value":1.5,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SCNX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SCNX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SCNX","date":"2026-02-13","current":-0.232167,"percent":0.489914,"low":-4.335221,"twenty":-1.176993,"median":-0.828904,"eighty":1.372015,"high":3.580326,"avg":-0.132842,"sd":1.748783,"marketCap":17491565},"quantilePoints":[{"date":"2024-09-27","current":-0.598388,"twenty":-0.613397,"median":-0.60738,"eighty":-0.601331,"marketCap":10677383},{"date":"2024-10-04","current":-0.575439,"twenty":-0.613397,"median":-0.603293,"eighty":-0.596854,"marketCap":10267882},{"date":"2024-10-11","current":-0.569717,"twenty":-0.610449,"median":-0.596691,"eighty":-0.575112,"marketCap":10165786},{"date":"2024-10-18","current":-3.316594,"twenty":-3.320439,"median":-0.603293,"eighty":-0.579563,"marketCap":59179885},{"date":"2024-10-25","current":-3.532893,"twenty":-3.381003,"median":-0.61388,"eighty":-0.587997,"marketCap":63039443},{"date":"2024-10-31","current":-3.835472,"twenty":-3.470407,"median":-1.920019,"eighty":-0.593421,"marketCap":68438535},{"date":"2024-11-08","current":-3.92083,"twenty":-3.680939,"median":-3.316594,"eighty":-0.596527,"marketCap":69961625},{"date":"2024-11-15","current":3.401097,"twenty":-3.547313,"median":-1.920019,"eighty":-0.574948,"marketCap":68584767},{"date":"2024-11-22","current":3.456572,"twenty":-3.511744,"median":-0.611468,"eighty":3.395976,"marketCap":69703464},{"date":"2024-11-29","current":3.136519,"twenty":-3.477174,"median":-0.603293,"eighty":3.362691,"marketCap":63249440},{"date":"2024-12-06","current":3.110915,"twenty":-3.463831,"median":-0.596691,"eighty":3.285878,"marketCap":62733118},{"date":"2024-12-13","current":3.337086,"twenty":-3.450219,"median":-0.582313,"eighty":3.360949,"marketCap":67293962},{"date":"2024-12-20","current":3.469375,"twenty":-3.422821,"median":-0.572987,"eighty":3.384019,"marketCap":69961625},{"date":"2024-12-27","current":2.837803,"twenty":-3.405517,"median":1.134043,"eighty":3.366915,"marketCap":57225683},{"date":"2025-01-03","current":2.561875,"twenty":-3.372831,"median":2.613767,"eighty":3.343052,"marketCap":51661454},{"date":"2025-01-10","current":2.200068,"twenty":-3.341588,"median":2.571818,"eighty":3.331965,"marketCap":44365450},{"date":"2025-01-17","current":1.983099,"twenty":-3.320439,"median":2.304552,"eighty":3.323431,"marketCap":39990159},{"date":"2025-01-24","current":1.820372,"twenty":-3.285831,"median":2.061208,"eighty":3.308922,"marketCap":36708691},{"date":"2025-01-31","current":1.69236,"twenty":-3.231997,"median":1.995032,"eighty":3.279477,"marketCap":34127269},{"date":"2025-02-07","current":1.431997,"twenty":-2.180107,"median":1.896311,"eighty":3.250031,"marketCap":28876920},{"date":"2025-02-14","current":1.375585,"twenty":-0.618263,"median":1.823627,"eighty":3.227841,"marketCap":27739344},{"date":"2025-02-21","current":1.184652,"twenty":-0.615326,"median":1.76613,"eighty":3.213059,"marketCap":23889088},{"date":"2025-02-28","current":1.145598,"twenty":-0.611128,"median":1.69236,"eighty":3.194897,"marketCap":23101536},{"date":"2025-03-07","current":1.045792,"twenty":-0.608474,"median":1.646775,"eighty":3.193463,"marketCap":21088902},{"date":"2025-03-14","current":0.538084,"twenty":-0.602312,"median":1.540482,"eighty":3.184314,"marketCap":10850721},{"date":"2025-03-21","current":0.733356,"twenty":-0.598212,"median":1.425488,"eighty":3.168951,"marketCap":14788483},{"date":"2025-03-28","current":0.715999,"twenty":-0.597181,"median":1.375585,"eighty":3.16127,"marketCap":14438460},{"date":"2025-04-04","current":1.435684,"twenty":-0.595056,"median":1.425488,"eighty":3.153589,"marketCap":13015619},{"date":"2025-04-11","current":1.12784,"twenty":-0.589891,"median":1.375585,"eighty":3.136519,"marketCap":10224770},{"date":"2025-04-17","current":1.246836,"twenty":-0.582313,"median":1.328698,"eighty":3.136519,"marketCap":11303565},{"date":"2025-04-25","current":1.311304,"twenty":-0.575439,"median":1.30873,"eighty":3.110915,"marketCap":11888016},{"date":"2025-05-02","current":1.325247,"twenty":-0.574621,"median":1.311304,"eighty":3.085311,"marketCap":12014418},{"date":"2025-05-09","current":1.290735,"twenty":-0.571352,"median":1.304933,"eighty":2.846338,"marketCap":11701542},{"date":"2025-05-16","current":-0.774291,"twenty":-0.575439,"median":1.297499,"eighty":2.837803,"marketCap":11803474},{"date":"2025-05-23","current":-0.765773,"twenty":-0.597508,"median":1.28756,"eighty":2.645772,"marketCap":11673621},{"date":"2025-05-30","current":-0.779626,"twenty":-0.610109,"median":1.27693,"eighty":2.645772,"marketCap":11884796},{"date":"2025-06-06","current":-0.894836,"twenty":-0.730719,"median":1.246836,"eighty":2.594563,"marketCap":13641086},{"date":"2025-06-13","current":-0.959367,"twenty":-0.765773,"median":1.225767,"eighty":2.581761,"marketCap":14624818},{"date":"2025-06-20","current":-0.856031,"twenty":-0.771761,"median":1.212713,"eighty":2.569829,"marketCap":13049535},{"date":"2025-06-27","current":-0.841318,"twenty":-0.780624,"median":1.184652,"eighty":2.512356,"marketCap":12825244},{"date":"2025-07-03","current":-1.247608,"twenty":-0.792738,"median":1.179469,"eighty":2.409427,"marketCap":19018822},{"date":"2025-07-11","current":-1.411087,"twenty":-0.813268,"median":1.154073,"eighty":2.262758,"marketCap":21510943},{"date":"2025-07-18","current":-1.789672,"twenty":-0.855997,"median":1.145598,"eighty":2.175929,"marketCap":27282172},{"date":"2025-07-25","current":-1.746651,"twenty":-0.908602,"median":1.122616,"eighty":2.108316,"marketCap":26626350},{"date":"2025-08-01","current":-1.669213,"twenty":-0.977436,"median":1.076168,"eighty":2.04385,"marketCap":25445872},{"date":"2025-08-08","current":-2.380911,"twenty":-1.247608,"median":1.000228,"eighty":2.013475,"marketCap":36295155},{"date":"2025-08-15","current":-0.96959,"twenty":-1.381833,"median":0.872216,"eighty":1.999328,"marketCap":19518727},{"date":"2025-08-22","current":-0.980842,"twenty":-1.373229,"median":0.796277,"eighty":1.985962,"marketCap":19745239},{"date":"2025-08-29","current":-0.980746,"twenty":-1.319883,"median":0.733356,"eighty":1.970949,"marketCap":19743303},{"date":"2025-09-05","current":-0.893537,"twenty":-1.247608,"median":0.689962,"eighty":1.941441,"marketCap":17987698},{"date":"2025-09-12","current":-0.924958,"twenty":-1.220075,"median":0.629211,"eighty":1.895443,"marketCap":18620241},{"date":"2025-09-19","current":-0.916402,"twenty":-1.093717,"median":0.546763,"eighty":1.883542,"marketCap":18448004},{"date":"2025-09-26","current":-0.858058,"twenty":-1.027837,"median":-0.570534,"eighty":1.845235,"marketCap":17273474},{"date":"2025-10-03","current":-0.892899,"twenty":-1.021738,"median":-0.575439,"eighty":1.825579,"marketCap":17974872},{"date":"2025-10-10","current":-0.787446,"twenty":-1.012393,"median":-0.59383,"eighty":1.815599,"marketCap":15852002},{"date":"2025-10-17","current":-0.608083,"twenty":-1.007669,"median":-0.598388,"eighty":1.784356,"marketCap":12241257},{"date":"2025-10-24","current":-2.680141,"twenty":-1.007669,"median":-0.596691,"eighty":1.730959,"marketCap":53953668},{"date":"2025-10-31","current":-0.791363,"twenty":-1.019031,"median":-0.603293,"eighty":1.707894,"marketCap":15930858},{"date":"2025-11-07","current":-1.280832,"twenty":-1.093717,"median":-0.610618,"eighty":1.69236,"marketCap":25784310},{"date":"2025-11-14","current":-1.151144,"twenty":-1.207623,"median":-0.619577,"eighty":1.689756,"marketCap":23173577},{"date":"2025-11-21","current":-1.10301,"twenty":-1.174718,"median":-0.731804,"eighty":1.679333,"marketCap":22671994},{"date":"2025-11-28","current":-1.184253,"twenty":-1.184253,"median":-0.746883,"eighty":1.679299,"marketCap":24341921},{"date":"2025-12-05","current":-1.19809,"twenty":-1.186625,"median":-0.754071,"eighty":1.614251,"marketCap":24626336},{"date":"2025-12-12","current":-1.198288,"twenty":-1.205799,"median":-0.765773,"eighty":1.560053,"marketCap":24630400},{"date":"2025-12-19","current":-0.985197,"twenty":-1.202636,"median":-0.770075,"eighty":1.540482,"marketCap":20250398},{"date":"2025-12-26","current":-1.058534,"twenty":-1.199158,"median":-0.774377,"eighty":1.505767,"marketCap":21757801},{"date":"2026-01-02","current":-1.008127,"twenty":-1.198169,"median":-0.779626,"eighty":1.460246,"marketCap":20721715},{"date":"2026-01-09","current":-1.092533,"twenty":-1.19726,"median":-0.785773,"eighty":1.433472,"marketCap":22456651},{"date":"2026-01-16","current":-1.033232,"twenty":-1.190657,"median":-0.792532,"eighty":1.424186,"marketCap":21237727},{"date":"2026-01-23","current":-1.008127,"twenty":-1.185676,"median":-0.799919,"eighty":1.415507,"marketCap":20721715},{"date":"2026-01-30","current":-0.962267,"twenty":-1.184253,"median":-0.804018,"eighty":1.403888,"marketCap":19779080},{"date":"2026-02-06","current":-0.84999,"twenty":-1.182312,"median":-0.81198,"eighty":1.386796,"marketCap":17471250},{"date":"2026-02-13","current":-0.850978,"twenty":-1.176993,"median":-0.828904,"eighty":1.372015,"marketCap":17491565}],"updateTime":1771392781455},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SCNX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608787246","title":"BUZZ-U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney","url":"https://stock-news.laohu8.com/highlight/detail?id=2608787246","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608787246?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:17","pubTimestamp":1770128229,"startTime":"0","endTime":"0","summary":"** Palantir Technologies Inc PLTR.O:BUZZ - Jumps as US government contracts boost quarterly sales nL4N3YZ0PE** Merck & Co Inc MRK.N:BUZZ - Falls on downbeat 2026 profit and sales forecasts nL4N3YZ0U8     ** Newmont Corp NEM.N:     ** Gold Fields Ltd GFI.N:** AngloGold Ashanti PLC AU.N: ** Harmony Gold Mining Co Ltd HMY.N:BUZZ - Gold, silver miners gain as metal prices edge higher after two-session rout nL4N3YZ0ST** McDonald's Corp MCD.N:BUZZ - Up after brokerage BTIG upgrades to 'buy'  nL6N3YY0WK** SoFi Technologies Inc SOFI.O:BUZZ - Rises after J.P. Morgan upgrades to 'overweight' nL6N3YZ0MY     ** Rio Tinto PLC RIO.N:              ** BHP Group Ltd BHP.N:** Southern Copper Corp SCCO.N: ** Freeport-McMoRan Inc FCX.N:BUZZ - Copper miners rise on China stockpiling, stronger risk sentiment nL4N3YZ0W3** PepsiCo Inc PEP.O:BUZZ - Falls after reaffirming annual earnings forecast despite Q4 revenue beat nL4N3YZ0YH** FedEx Corp FDX.N:BUZZ - Gains after Bernstein upgrades rating to 'outperform' ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nL6N3YZ0PY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLTA","PLTW","LU1223082196.USD","PTIR","DVA","AU","MCD","RARE","NEM","EVR","DIS","SOFX","SCNX","FDX","MRK","PLTY","PLTG","BHP.AU","JBLU","PLT","RIO.UK","MPC","IVVD","LU1066051225.USD","PYPY","PLTZ","RIO.AU","SOC","PEP","PYPG","PLTD","PLYY","GTBP","PLOO","HPQ","PLTU","OVV","BK4559","ETN","ADM","WST","VSEC","BALL","LU1162221912.USD"],"gpt_icon":1},{"id":"2608879095","title":"BUZZ-Scienture jumps after expanding access to hypertension drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2608879095","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608879095?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:17","pubTimestamp":1770124624,"startTime":"0","endTime":"0","summary":"BUZZ-Scienture jumps after expanding access to hypertension drug** Shares of drugmaker Scienture Holdings SCNX.O rise 10.34% to $0.4993 premarket** Co says it has expanded access to Arbli, its ready-to-use liquid losartan for high blood pressure** Losartan treats hypertension, a condition where consistently high blood pressure increases the risk of stroke and heart disease - SCNX** Co says Arbli now available at more than 2,500 healthcare sites, with coverage for 100 million insured Americans** Expects continued Arbli prescription growth in Q1 and wider insurance and pharmacy coverage** Says its nasal spray for opioid overdose emergencies, Rezenopy, is set for a U.S. launch in Q2 2026 ** Shares fell ~92% in 2025","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nL4N3YZ1A5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2608791448","title":"Scienture Holdings Reaffirms Q1 2026 Growth Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2608791448","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608791448?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:05","pubTimestamp":1770123916,"startTime":"0","endTime":"0","summary":"Scienture Holdings Inc. outlined its outlook for the first quarter of 2026, expecting continued sequential growth in prescription volumes and adoption of ARBLI, its FDA-approved oral suspension of losartan potassium. The company anticipates improved commercial efficiency as initial launch investments begin generating recurring demand. Scienture also projects further expansion of payer and pharmacy engagement, which is expected to broaden patient access across both commercial and government sectors. The company reported a significant strengthening of its balance sheet in the last quarter, including a substantial reduction in outstanding debt and an increase in its cash position to approximately $7.0 million as of December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDLc0zmbC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014021.USD","LU0314104364.USD","BK4588","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","NDAQ","LU2210150020.SGD","SCNX","SG9999014039.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","BK4167","IE00BKPKM429.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2608871631","title":"SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium","url":"https://stock-news.laohu8.com/highlight/detail?id=2608871631","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608871631?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:05","pubTimestamp":1770123900,"startTime":"0","endTime":"0","summary":"Company highlights accelerating access and revenue growth for ARBLI and confirms REZENOPY launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million Ou","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/03/3231048/0/en/SCIENTURE-Provides-Commercial-Update-on-ARBLI-the-First-FDA-Approved-Ready-to-Use-Oral-Suspension-of-Losartan-Potassium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNX","ARB","BK4167"],"gpt_icon":0},{"id":"2603619598","title":"BUZZ-Scienture Holdings jumps after U.S. FDA clears opioid overdose spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2603619598","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603619598?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:25","pubTimestamp":1768397155,"startTime":"0","endTime":"0","summary":"BUZZ-Scienture Holdings jumps after U.S. FDA clears opioid overdose spray** Shares of specialty pharma firm Scienture Holdings SCNX.O rise 19.99% to $0.6472 premarket** Co says U.S. FDA has approved a new high-dose nasal spray, Rezenopy, for treating opioid overdoses** Says spray delivers 10mg naloxone to reverse overdoses from powerful opioids including fentanyl** Adds SCNX holds exclusive U.S. sales rights; Summit Biosciences will manufacture the product** Patent protection runs through February 2041; naloxone market worth $154 million, with 9.3 million units sold annually - IQVIA data** As of last close, stock down ~92% over the past year","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nL4N3YF19H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0648001328.SGD","LU1201861165.SGD","LU0528227936.USD","LU0477156797.USD","LU0198837287.USD","LU0130518102.USD","BK4121","BK4530","LU1791710582.SGD","LU0980610538.SGD","LU0648000940.SGD","LU0130103400.USD","LU1261432733.SGD","LU1989764664.SGD","LU0130517989.USD","LU1989764748.USD","BK4585","LU0130102774.USD","LU0882574055.USD","IQV","LU1791710400.SGD","SCNX","BK4167","LU1201861249.SGD","LU0477156953.USD","BK4588"],"gpt_icon":0},{"id":"2603616116","title":"Scienture Announces Issuance of Orange Book-Listable Patent Covering Rezenopy™, the Highest Dosage Naloxone Hcl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616116","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603616116?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:05","pubTimestamp":1768395900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nTUA3JWGMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2603616558","title":"EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616558","media":"Benzinga_recent_news","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603616558?lang=en_us&edition=fundamental","pubTime":"2026-01-14 20:51","pubTimestamp":1768395060,"startTime":"0","endTime":"0","summary":"New US patent strengthens protection for Rezenopy, the FDA-approved 10 mg naloxone nasal spray.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/14/Naloxone-And-Narcan-Nasal-Spray-In-The-E.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/14/Naloxone-And-Narcan-Nasal-Spray-In-The-E.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/01/49901588/exclusive-penny-stock-scientures-partner-secures-us-patent-for-highest-dosage-naloxone-spray-for-emergency-opioid-overdose-treatment","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/01/49901588/exclusive-penny-stock-scientures-partner-secures-us-patent-for-highest-dosage-naloxone-spray-for-emergency-opioid-overdose-treatment","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2593348026","title":"BRIEF-Scienture Provides Update On The Commercial Launch Of Rezenopy","url":"https://stock-news.laohu8.com/highlight/detail?id=2593348026","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593348026?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:22","pubTimestamp":1766409727,"startTime":"0","endTime":"0","summary":"BRIEF-Scienture Provides Update On The Commercial Launch Of RezenopyDec 22 (Reuters) - Scienture Holdings Inc SCNX.O:SCIENTURE PROVIDES UPDATE ON THE COMMERCIAL LAUNCH OF REZENOPY, THE HIGHEST STRENGT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA1DGPVY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","SCNX"],"gpt_icon":0},{"id":"2593803154","title":"Scienture Holdings Launches High-Strength REZENOPY Naloxone Nasal Spray in U.S. Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2593803154","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593803154?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:05","pubTimestamp":1766408730,"startTime":"0","endTime":"0","summary":"Scienture Holdings Inc. has announced an update on the commercial launch of REZENOPY, a high-strength 10 mg naloxone HCl nasal spray, following its FDA approval in April 2024. Through an exclusive agreement with Summit Biosciences Inc., Scienture will oversee the U.S. commercialization of REZENOPY. The company plans to load the product into wholesale channels in the first quarter of 2026, with commercial availability expected in early Q2 2026. This initiative marks a significant expansion in Scienture’s product portfolio, aiming to address the growing need for effective opioid overdose treatments in the U.S. market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scienture Holdings Inc. published the original content used to generate th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDLbp8Fnv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4167","NDAQ","SG9999014005.SGD","BK4588","SG9999014013.SGD","SCNX","SG9999014039.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","LU0314104364.USD","BK4112","SG9999014021.USD","IE00BGHQF748.EUR","LU2210150020.SGD"],"gpt_icon":0},{"id":"2593906480","title":"Scienture Holdings Inc - Rezenopy Expected Commercially Available Early Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2593906480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593906480?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:05","pubTimestamp":1766408700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA1DGPVY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2593480575","title":"SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2593480575","media":"GlobeNewswire","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593480575?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:05","pubTimestamp":1766408700,"startTime":"0","endTime":"0","summary":"U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec.  22, 2025  (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for exist","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/22/3209189/0/en/SCIENTURE-Provides-Update-on-the-Commercial-Launch-of-REZENOPY-the-Highest-Strength-Naloxone-HCl-Life-Saving-Opioid-Overdose-Emergency-Treatment-Approved-by-the-FDA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2590713535","title":"Why Is Scienture Stock Gaining Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590713535","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590713535?lang=en_us&edition=fundamental","pubTime":"2025-12-10 22:53","pubTimestamp":1765378380,"startTime":"0","endTime":"0","summary":"Scienture stock is climbing after the company partnered with BlinkRx to expand national access to its new FDA-approved liquid losartan therapy, Arbli.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/10/Scienture-Holdings--Inc-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/10/Scienture-Holdings--Inc-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49306538/why-is-scienture-stock-gaining-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49306538/why-is-scienture-stock-gaining-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2590587588","title":"BRIEF-SCIENTURE And BlinkRx Announce Strategic Collaboration To Expand Patient Access To Arbli, The First FDA-Approved Ready-To-Use Oral Suspension Of Losartan Potassium","url":"https://stock-news.laohu8.com/highlight/detail?id=2590587588","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590587588?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:06","pubTimestamp":1765371990,"startTime":"0","endTime":"0","summary":"BRIEF-SCIENTURE And BlinkRx Announce Strategic Collaboration To Expand Patient Access To Arbli, The First FDA-Approved Ready-To-Use Oral Suspension Of Losartan PotassiumDec 10 (Reuters) - Scienture Ho","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA1CKV4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","SCNX"],"gpt_icon":0},{"id":"2590587829","title":"Scienture and Blinkrx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium","url":"https://stock-news.laohu8.com/highlight/detail?id=2590587829","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590587829?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:05","pubTimestamp":1765371900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA1CKV4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","SCNX"],"gpt_icon":0},{"id":"2590587580","title":"Scienture Holdings Inc - Arbli Expected on Blinkrx Platform in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590587580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590587580?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:05","pubTimestamp":1765371900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA1CKV4T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","SCNX"],"gpt_icon":0},{"id":"2588530450","title":"SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588530450","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588530450?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:05","pubTimestamp":1764680700,"startTime":"0","endTime":"0","summary":"COMMACK, NY, Dec.  02, 2025  (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced va","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3197898/0/en/SCIENTURE-to-Participate-in-the-iAccess-Alpha-Virtual-Best-Ideas-Winter-Investment-Conference-2025-on-December-9-10-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","SCNX"],"gpt_icon":0},{"id":"2583059682","title":"Scienture Holdings Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2583059682","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583059682?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:03","pubTimestamp":1763157803,"startTime":"0","endTime":"0","summary":"Scienture Holdings Inc. held its 2025 Annual Meeting of Stockholders on November 12, 2025. Stockholders voted on several key proposals, including the election of five directors to the board. Proposals also included the approval of a potential future offering of common stock that could result in the issuance of more than 20% of currently outstanding shares at a price below the minimum price, granting the board discretion to amend the charter to effect a reverse stock split at a ratio between one-for-two and one-for-fifty, and the approval of an adjournment of the meeting if necessary to solicit additional proxies. Each of these proposals was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scienture Holdings Inc. published the o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL8rBtdX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","SCNX"],"gpt_icon":0},{"id":"2583443598","title":"Scienture reports Q3 EPS (19c) vs. ($1.34) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2583443598","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583443598?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:15","pubTimestamp":1763039724,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $590,050 vs. $64,861 last year. “Q3 was a transformational quarter for Scienture (SCNX) as we commenced sales of Arbli,” comment...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scienture-reports-q3-eps-19c-vs-1-34-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scienture-reports-q3-eps-19c-vs-1-34-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","SCNX"],"gpt_icon":0},{"id":"2583596155","title":"SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583596155","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583596155?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:05","pubTimestamp":1763039100,"startTime":"0","endTime":"0","summary":"Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli, the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for Hypertensi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187305/0/en/SCIENTURE-Reports-Q3-2025-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARB","BK4167","SCNX"],"gpt_icon":0},{"id":"2583560663","title":"EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2583560663","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583560663?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:50","pubTimestamp":1763038258,"startTime":"0","endTime":"0","summary":"Scienture&#39;s Q3 revenue surged on Arbli sales, debt dropped, and cash rose to $8 million ahead of its planned Rezenopy launch in early 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/25/11/48830985/exclusive-scienture-delivers-q3-revenue-jump-with-arbli-sales-and-debt-reduction","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNX","BK4167"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}]}}